Sanofi completes acquisition of Vicebio, expanding respiratory vaccine portfolio.
ByAinvest
Thursday, Dec 4, 2025 5:05 am ET1min read
SNY--
Sanofi has completed its acquisition of Vicebio Ltd, gaining an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV). The acquired vaccine candidate complements Sanofi's position in respiratory vaccines and expands its capabilities in vaccine design and development. The acquisition is expected to increase physician and patient choice in RSV and HMPV treatment.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet